Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

Journal:

Journal of Clinical Oncology

Published:

2025-12-23

DOI:

10.1200/jco-25-01587

Affiliations:

18

Authors:

31

Go to article

Institutions	Authors	Share
University of Cambridge, United Kingdom (UK)	16.833333 16.833333	0.54
Norfolk and Norwich University Hospitals NHS Foundation Trust, United Kingdom (UK)	3.000000	0.10
Cambridge University Hospitals NHS Foundation Trust, United Kingdom (UK)	2.666667	0.09
AstraZeneca United States, United States of America (USA)	2.000000	0.06
University Hospitals of Leicester NHS Trust (UHL), United Kingdom (UK)	1.500000	0.05
Nottingham University Hospitals NHS Trust (NUH), United Kingdom (UK)	1.500000	0.05
West Suffolk Hospital, West Suffolk NHS Foundation Trust, United Kingdom (UK)	1.000000	0.03
North West Anglia NHS Foundation Trust, United Kingdom (UK)	1.000000	0.03
University of Leicester, United Kingdom (UK)	0.500000	0.02
Athens University of Economics and Business (AUEB), Greece	0.500000	0.02
The University of Nottingham (UoN), United Kingdom (UK)	0.500000	0.02

Interested in Cardiovascular Medicine and Haematology?